Leukocyte Patents (Class 424/93.71)
-
Publication number: 20140335149Abstract: The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having on its surface at least leukocytes and/or platelets, a method for producing the same, a device for producing the same, and a method for treating wound sites using the same.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Ushio IWAMOTO, Yasuo TOKUSHIMA, Nobuya KITAGUCHI
-
Publication number: 20140328899Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.Type: ApplicationFiled: July 7, 2012Publication date: November 6, 2014Applicants: SHAARE ZEDEK MEDICAL CENTER, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda
-
Patent number: 8877182Abstract: A method of obtaining expanded and activated natural killer (NK) cells with the phenotype CD3?CD56+ and NK-like T cells with the phenotype CD3+CD56+ comprises providing a cell sample of peripheral blood from a tumor bearing subject; isolating cells from the blood sample and re-suspending the cells in growth medium; adding the isolated cells to a closed cell culture bag bioreactor at a concentration of about 0.5×106 to about 2×106/ml of growth medium; incubating and expanding the cells of step ii) with rocking motion agitation and heating until at least 50% of the expanded cell population comprises activated NK cells and NK-like T cells; and harvesting the expanded cell suspension of therapeutically active NK-cells and NK-like T cells from the bioreactor, wherein the cells exhibit an increased cytotoxicity compared to freshly isolated cells as determined by an in vitro cytotoxicity test.Type: GrantFiled: March 25, 2010Date of Patent: November 4, 2014Assignee: Cellprotect Nordic Pharmaceuticals ABInventor: Evren Alici
-
Publication number: 20140322188Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.Type: ApplicationFiled: April 26, 2013Publication date: October 30, 2014Applicant: ENZO BIOCHEM, INC.Inventors: RICHARD NUSSENBLATT, BAOYING LIU, LAI WEI, ELAZAR RABBANI, JAMES J. DONEGAN
-
Patent number: 8865160Abstract: The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various diseases and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria.Type: GrantFiled: February 9, 2009Date of Patent: October 21, 2014Assignee: University of South AlabamaInventors: Glenn Wilson, Susan Ledoux, Mikhail Alexeyev, Inna Shokolenko, Mark N. Gillespie
-
Publication number: 20140308260Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.Type: ApplicationFiled: October 5, 2012Publication date: October 16, 2014Inventors: Bryan T. Oronsky, Jan Scicinski, Susan Knox, William Fitch, Frans A. Kuypers, Marcel Fens, Sandra Larkin, Pedro Cabrales, Chad Brouse
-
Publication number: 20140308261Abstract: This invention concerns HY epitopic polypeptides specifically presented by the HLA-DR7 molecule, a method for preparing these epitopic polypeptides, isolated T-lymphocytes capable of specifically recognizing an epitope from these polypeptides or from a polypeptide comprising the complete sequence of the protein encoded by the RPS4Y gene and presented by the HLA-DR7 molecule expressed on the surface of antigen-presenting cells, a method for preparing these T-lymphocytes, as well as the use of these epitopic polypeptides and these T-lymphocytes as medicaments, in particular for the treatment of cancers of immune cells.Type: ApplicationFiled: November 21, 2012Publication date: October 16, 2014Inventors: Assia El Jaafari, Dominique Rigal, Diane Scott
-
Publication number: 20140302096Abstract: The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.Type: ApplicationFiled: February 6, 2014Publication date: October 9, 2014Applicant: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Dolores J. SCHENDEL, Anke ZOBYWALSKI, Iris BIGALKE
-
Publication number: 20140302097Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
-
Publication number: 20140302050Abstract: Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Paraic Anthony Kenny, Kelly Susan Levano Najarro, Eric Hoonee Jung
-
Publication number: 20140301996Abstract: The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.Type: ApplicationFiled: May 24, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF BIRMINGHAM, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Dale T. Umetsu, Rosemarie Helena De Kruyff, Ya-Jen Chang, Petr Illarionov
-
Patent number: 8852581Abstract: A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed bowel segment, expanding the T cells in vitro, and re-infusing the expanded T cell to the patient. Also disclosed are methods for obtaining sentinel nodes, for expanding T cells, for re-establishing the TH1/TH2 balance in the patient suffering from Crohn's disease, and corresponding uses of the expanded T cells, the cytokine and of antigen extract, as well as of correspondingly activated and expanded T cells.Type: GrantFiled: August 22, 2006Date of Patent: October 7, 2014Assignee: ITH Immune Therapy Holdings ABInventors: Ola Winqvist, Magnus Thorn
-
Publication number: 20140294793Abstract: The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Inventors: Dan R. Littman, Sang-Won Kim
-
Publication number: 20140294792Abstract: This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.Type: ApplicationFiled: February 21, 2014Publication date: October 2, 2014Applicant: The Board of Trustees of the University of IllinoisInventor: Bellur Prabhakar
-
Publication number: 20140286906Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Inventors: Daniel Bilbao Cortes, Nadia Rosenthal, Luisa Luciani
-
Publication number: 20140271588Abstract: Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Matthew D. LANDRIGAN, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY, David L. SUTER
-
Publication number: 20140273077Abstract: A closed system suitable for the aseptic culturing therapeutic cells comprises a vessel comprising: a gas permeable portion suitable for supporting cell growth and allowing delivery of gases to the cells during culturing, a vent comprising a conduit having an exterior orifice and an interior orifice spaced apart therefrom, the vent extending from the exterior of the system into the internal volume of the vessel and terminating therein with the interior orifice, wherein the interior orifice is arranged such that during filling and emptying of liquid medium it is not susceptible to blockage by liquid, the exterior orifice is adapted to connect to an aseptic filter thereby allowing passage of gases through the filter into the vessel or out of the vessel, as required to achieve the entry and exit of fluids and cells into the vessel, a port or ports adapted to allow introduction of fluids and cells aseptically into the vessel, and a port or ports adapted to allow fluids to exit the system without exposing the systType: ApplicationFiled: October 19, 2012Publication date: September 18, 2014Inventors: Rainer Ludwig Knaus, Gavin Holms, Katy Rebecca Newton, Tina Lesley Crombie, Andrew Roy MacLeod Provan
-
Publication number: 20140271587Abstract: Methods and therapeutic compositions for treating respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and devices for administering the therapeutic compositions. Methods for treatment include producing a protein solution, producing a concentrated bone marrow aspirate (cBMA), optionally combining the protein solution and cBMA to form an therapeutic composition, and optionally saturating the autologous therapeutic composition with hydrogen gas, and administering the therapeutic composition to a subject in need thereof. The present methods, compositions and devices are useful for treating COPD and the progression of COPD.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: BIOMET BIOLOGICS, LLCInventors: Matthew D. LANDRIGAN, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY
-
Publication number: 20140271725Abstract: Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dipeptidyl peptidase (DPP) IV activity and/or structural homologues thereof (DASH) serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of T-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. For example, the compound that inhibits a plurality of mammalian DASH serine proteases may be t-butylGly-boroPro.Type: ApplicationFiled: November 15, 2012Publication date: September 18, 2014Inventor: William W. Bachovchin
-
Publication number: 20140255368Abstract: A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells.Type: ApplicationFiled: March 11, 2014Publication date: September 11, 2014Inventors: Julian Kim, Hallie Graor, Mei Zhang, Anthony Visioni
-
Publication number: 20140248248Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.Type: ApplicationFiled: May 22, 2014Publication date: September 4, 2014Applicant: Sunnybrook Health Sciences CentreInventors: JUAN CARLOS ZUNIGA-PFLUCKER, GENEVE AWONG, ROSS LA MOTTE-MOHS
-
Publication number: 20140242053Abstract: A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of antigen-presenting cells. Other applications are also described.Type: ApplicationFiled: March 11, 2014Publication date: August 28, 2014Applicant: BIOGENCELL, LTDInventor: Yael Porat
-
Publication number: 20140234282Abstract: Compositions and methods comprising ampicillin or salts and derivative thereof for the treatment of delaying the on-set of type I diabetes are provided.Type: ApplicationFiled: September 20, 2012Publication date: August 21, 2014Applicant: STEM CELL MEDICINE LTD.Inventors: Irun R. Cohen, Felix Mor
-
Publication number: 20140234281Abstract: The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.Type: ApplicationFiled: November 21, 2013Publication date: August 21, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Ronald BERENSON, Mark BONYHADI, Dale KALAMASZ
-
Publication number: 20140220085Abstract: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or both of them have charges with different electricity. The biomedical material is utilized for dentistry, orthopedics, wound healing or medical beauty and applied in the repair and regeneration of various soft and hard tissues.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Industrial Technology Research InstituteInventors: Pei-Yi TSAI, Yi-Hung WEN, Zhi-Jie HUANG, Pei-Shan LI, Hsin-Hsin SHEN, Yi-Hung LIN, Chih-Hung CHEN
-
Publication number: 20140219979Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pisner, Ofer Lider
-
Publication number: 20140219978Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: December 13, 2013Publication date: August 7, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8795653Abstract: The invention provides isolated regulatory immune cells as well as cell cultures and conditioned media derived therefrom. Also provided are methods of repressing B cell autoantibody production and/or secretion and methods of treating autoimmune disorders using regulatory immune cells or precursors thereto such as hematopoietic stem cells (HSC). The invention also provides methods of repressing B cell autoantibody production and/or secretion and methods of treating autoimmune disorders by administration of HSC and Macrophage-Colony Stimulating Factor (M-CSF). Further provided are methods of diagnosing in a mammalian subject a defect in regulatory cell mediated repression of autoantibody secretion by B cells.Type: GrantFiled: March 15, 2006Date of Patent: August 5, 2014Assignee: The University of North Carolina at Chapel HillInventors: Barbara J. Vilen, Michelle Kilmon, Jennifer A. Rutan
-
Publication number: 20140212397Abstract: Methods for transfusing blood to a mammalian subject. The method includes obtaining a unit of blood, rejuvenating the blood with an enhancement composition, measuring 2,3-DPG concentration of the blood, and delivering the blood to a subject.Type: ApplicationFiled: March 15, 2013Publication date: July 31, 2014Inventors: Alan GRAY, Joel C. HIGGINS, Matthew D. LANDRIGAN, Grant CUNNINGHAM
-
Publication number: 20140212446Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.Type: ApplicationFiled: April 8, 2014Publication date: July 31, 2014Applicant: The Trustees of The University of PennsylvaniaInventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
-
Publication number: 20140212398Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.Type: ApplicationFiled: September 6, 2012Publication date: July 31, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair Reisner, Yaki Eidelstein, Eran Ophir, Assaf Lask, Ran Afik, Noga Or-Geva, Esther Bachar-Lustig
-
Publication number: 20140193382Abstract: Methods and compositions are provided for the identification and isolation of mammalian HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC. The methods of the invention provide a means to obtain enriched HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC populations.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicant: ESCAPE THERAPEUTICS, INC.Inventor: Basil M. HANTASH
-
Publication number: 20140193385Abstract: A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: IMMUNOVATIVE THERAPIES, LTD.Inventor: Michael Har-Noy
-
Publication number: 20140186319Abstract: A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34+ hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.Type: ApplicationFiled: July 26, 2013Publication date: July 3, 2014Applicant: Case Western Reserve UniversityInventor: Rose C. Beck
-
Publication number: 20140178394Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.Type: ApplicationFiled: May 31, 2012Publication date: June 26, 2014Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Marc Lopez, Daniel Olive
-
Publication number: 20140178348Abstract: Methods using DNA Methylation arrays are provided for identifying a cell or mixture of cells and for quantification of alterations in distribution of cells in blood or in tissues, and for diagnosing, prognosing and treating disease conditions, particularly cancer. The methods use fresh and archival samples.Type: ApplicationFiled: November 25, 2013Publication date: June 26, 2014Applicants: The Regents of the University of California, Brown UniversityInventors: Karl Kelsey, Eugene Andres Houseman, John Wiencke, William P. Accomando, JR., Carmen Marsit
-
Publication number: 20140170221Abstract: The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes.Type: ApplicationFiled: November 8, 2013Publication date: June 19, 2014Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Bruce D. Walker, Richard Bradley Jones
-
Publication number: 20140161782Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.Type: ApplicationFiled: February 17, 2014Publication date: June 12, 2014Applicant: Targazyme, Inc.Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh
-
Publication number: 20140154274Abstract: The present invention provides medical uses and methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses for the intralymphatic administration of cellular therapies.Type: ApplicationFiled: January 12, 2012Publication date: June 5, 2014Applicants: TIGENIX NV, TIGENIX S.A.U.Inventors: Eleuterio Lombardo, Wilfried Dalemans
-
Publication number: 20140154227Abstract: The present invention provides a population of mesenchymal cells that do not express the cell surface markers CD112 and/or CD155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.Type: ApplicationFiled: March 12, 2012Publication date: June 5, 2014Inventors: Javier Garcia Casado, Raquel Tarazona Lafarge, Olga De La Rosa
-
Publication number: 20140154228Abstract: The invention relates to a method for generation of T cell preparations that are specific for at least one target antigen, comprising the steps of expanding lymphoid cells in vitro in the presence of a target antigen or peptide fragments thereof in an expansion step, isolating cells that secrete interferon gamma and culturing, the cells in the presence of interleukin 2 and interleukin 7 and either an inhibitor of the mTOR Complex 1, or in the presence of an inhibitor of IL-2/IL-2R interaction. The invention further relates to preparations obtained by the method of the invention.Type: ApplicationFiled: June 11, 2012Publication date: June 5, 2014Inventors: Hans-dieter Volk, Michael Schmuck, Petra Reinke
-
Patent number: 8741642Abstract: Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) bryostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases.Type: GrantFiled: October 21, 2011Date of Patent: June 3, 2014Assignee: Virginia Commonwealth UniversityInventors: Masoud H. Manjili, Harry D. Bear, Maciej Kmieciak
-
Publication number: 20140147482Abstract: The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.Type: ApplicationFiled: January 13, 2014Publication date: May 29, 2014Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Ayesha MAHMOOD, Anatoly KACHURIN, William WARREN, Russell HIGBEE
-
Publication number: 20140147455Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the comcomitant removal of T-cells associated with autoimmune disorders.Type: ApplicationFiled: October 24, 2013Publication date: May 29, 2014Applicant: OPKO Pharmaceuticals, LLCInventors: Phillip FROST, Thomas Kodadek
-
Publication number: 20140141026Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.Type: ApplicationFiled: July 12, 2013Publication date: May 22, 2014Applicant: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuR Gesundheit und Umwelt GmbHInventors: Dolores Jean Schendel, Susanne Wilde, Thomas Blankenstein
-
Publication number: 20140140987Abstract: A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin. The method further comprises administering an effective amount of a protein containing ApoA1/2/4, or administering an effective amount of a protein containing Factor II, Factor VII, Factor IX and Factor X in prothrombin complex concentrate. The method can further comprise administering an effective amount of fibrinogen, Factor VIII, high concentrate fibrinogen, thrombin. hepatitis B immune globulin (HBIG), anti-thrombin III (AT-III), protein C, fibronectin, protein S and protein M.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Patent number: 8728481Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: GrantFiled: July 17, 2012Date of Patent: May 20, 2014Assignee: Baylor Research InstituteInventors: Jacques F. Banchereau, SangKOn Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
-
Patent number: 8728465Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.Type: GrantFiled: June 17, 2009Date of Patent: May 20, 2014Assignee: Cedars-Sinai Medical CenterInventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
-
METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE
Publication number: 20140134145Abstract: Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4+CD25? T cells by using CD40-activated B cells. The regulatory T cells can be human T cells. In one embodiment, the alloantigen-specific human regulatory T cells can be CD4highCD25+Foxp3+ regulatory T cells.Type: ApplicationFiled: January 10, 2014Publication date: May 15, 2014Applicants: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, VERSITECH LIMITEDInventors: Wenwei Tu, Yu-Lung Lau, David Bram Lewis -
Publication number: 20140127246Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Bira Arya, Vladimir L. Larionov